Inhibitors of CaN have already been suggested to mitigate neuropathology in models of Alzheimer’s disease, strokes and, importantly, in mouse models of acquired prion disease [27,28,29,67,68,69,70,71,72]. Here, NUP214 is linked to prion disease.